CD276 and osteosarcoma: Xie et al. reported the ARTEMIS-002 trial, an open label randomized phase 2 study in patients with metastatic osteosarcoma and other sarcomas that had progressed on standard first line therapy, to evaluated the efficacy of HS-20093, a B7-H3 (B7 homologous 3, also called CD276) directed antibody drug conjugate (ADC) [77, 78].